M2698 manufacturers
- M2698
-
- $43.00 / 1mg
-
2025-11-10
- CAS:1379545-95-5
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
- M2698
-
- $43.00 / 1mg
-
2025-11-09
- CAS:1379545-95-5
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
- M2698
-
- $1.00 / 1KG
-
2019-12-26
- CAS:1379545-95-5
- Min. Order: 1KG
- Purity: 97%-99.9%
- Supply Ability: 100kg
|
| Product Name: | M2698 | | Synonyms: | M2698;(S)-4-(2-(azetidin-1-yl)-1-(4-chloro-3-(trifluoromethyl)phenyl)ethylamino)quinazoline-8-carboxamide;M2698 (MSC-2363318A);M2698; M-2698; M 2698; MSC-2363318A; MSC 2363318A; MSC2363318A;4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethylphenyl)ethylamino]quinazoline-8-carboxylic acid amide;8-Quinazolinecarboxamide, 4-[[(1S)-2-(1-azetidinyl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]-;4-{[(1S)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino}quinazoline-8-carboxamide;M2698, 10 mM in DMSO | | CAS: | 1379545-95-5 | | MF: | C21H19ClF3N5O | | MW: | 449.86 | | EINECS: | | | Product Categories: | | | Mol File: | 1379545-95-5.mol |  |
| | M2698 Chemical Properties |
| solubility | DMSO: soluble | | form | A solid | | color | White to off-white | | InChIKey | HXAUJHZZPCBFPN-QGZVFWFLSA-N | | SMILES | N1=C2C(C=CC=C2C(N)=O)=C(N[C@@H](C2=CC=C(Cl)C(C(F)(F)F)=C2)CN2CCC2)N=C1 |
| | M2698 Usage And Synthesis |
| Uses | M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity[1]. | | in vivo | M2698 (10-30 mg/kg/day; PO; 28 days) results in dose-dependent inhibition of tumor growth and results in tumor regression with the highest dose of 30 mg/kg[1].
?
M2698 (20 mg/kg/day; PO; 4 days) has a tumor:plasma exposure ratio of 12:1 over 24 hours and leads to increased levels of pAkt in tumor tissue[1].
?
The mean total concentration of M2698 after 16-hour infusion in rats is 1750 ng/g and 175 ng/mL in brain and plasma, respectively[1].
?
M2698 (po; 1, 5, 10, or 20 mg/kg/day; for 7 days) inhibits the phosphorylation of S6 in a dose-proportional manner over time after a single administration or daily treatments over 7 days[1].
| Animal Model: | Female nude mice bearing MDA-MB-468 tumors[1] | | Dosage: | 10, 20 and 30 mg/kg | | Administration: | PO; daily; for 28 days | | Result: | Resulted in dose-dependent inhibition of tumor growth and resulted in tumor regression with the highest dose of 30 mg/kg. |
| Animal Model: | Female SCID Beige mice with MDA-MB-453 xenografted[1] | | Dosage: | 20 mg/kg (Pharmacokinetic Analysis) | | Administration: | Daily; for 4 days | | Result: | Had a tumor:plasma exposure ratio of 12:1 over 24 hours.
|
| | IC 50 | p70S6K: 1 nM (IC50); Akt1: 1 nM (IC50); Akt3: 1 nM (IC50) | | References | [1] Machl A, et al. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. Am J Cancer Res. 2016 Mar 15;6(4):806-18. PMID:27186432 |
| | M2698 Preparation Products And Raw materials |
|